Please assess the completion status of the following clinical trial:

Trial Title: Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* (1) Patients who provided informed consent~* (2) Patients who are diagnosed as membranous nephropathy by renal biopsy~* (3) 18 years of age or older, male or female~Exclusion Criteria:~* (1) identification of Secondary factors such as infectious diseases, rheumatic diseases, tumors, drugs and so on~* (2) Previous medicine history of immunosuppressive medication and corticosteroids~* (3) Patients who are not expected to complete 6 months of follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cyclophosphamide (Type: None): Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
- Cyclosporin (Type: None): Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).